{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:51:27Z","timestamp":1793958687348,"version":"4.8.0"},"reference-count":70,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Bispecific antibodies (bsAbs), such as teclistamab, elranatamab, linvoseltamab, and talquetamab, have impressive efficacy in multiple myeloma (MM) but come with substantial infectious risks that do not dissipate over time. Immunoglobulin replacement therapy (IgRT), which includes IV and subcutaneous (SC) immunoglobulins, may lower these risks. In this viewpoint, we contrast primary IgRT prophylaxis (initiation regardless of IgG levels) with preemptive IgRT treatment (initiation only once IgG levels fall below a certain threshold) in this setting. We make evidence-based arguments for primary prophylaxis as a safer and simpler approach than preemptive IgG-guided IgRT. We also discuss strategies to improve the cost-effectiveness of IV and SC immunoglobulins across the world. Given the overwhelmingly favorable benefit-risk profile of IgRT, coupled with the limitations inherent to IgG measurements in MM, withholding IgRT access based on arbitrary IgG thresholds is neither scientifically sound nor clinically appropriate for patients with MM who are receiving bsAb therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016490","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T20:50:38Z","timestamp":1753131038000},"page":"4720-4726","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":42,"title":["Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"first","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6913-6526","authenticated-orcid":false,"given":"Meera","family":"Mohan","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Rejeski","sequence":"additional","affiliation":[{"name":"3Department of Medicine III, Hematology\/Oncology, LMU University Hospital, LMU Munich, Munich, Germany"},{"name":"4Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3972-6362","authenticated-orcid":false,"given":"Benjamin R.","family":"Puliafito","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5719-581X","authenticated-orcid":false,"given":"Diana D.","family":"Cirstea","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2510-6536","authenticated-orcid":false,"given":"Gurbakhash","family":"Kaur","sequence":"additional","affiliation":[{"name":"6Department of Medicine, The Mount Sinai Hospital, New Nork, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shonali","family":"Midha","sequence":"additional","affiliation":[{"name":"7Department of Medicine, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4838-9022","authenticated-orcid":false,"given":"Georgia J.","family":"McCaughan","sequence":"additional","affiliation":[{"name":"8Department of Haematology, St Vincent\u2019s Hospital, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6375-9981","authenticated-orcid":false,"given":"Nikhil M.","family":"Kumar","sequence":"additional","affiliation":[{"name":"9Department of Medicine, Fortis Memorial Research Institute, Gurugram, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4605-7470","authenticated-orcid":false,"given":"Nikita","family":"Mehra","sequence":"additional","affiliation":[{"name":"10Department of Medicine, Cachar Cancer Hospital & Research Centre, Silchar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9754-0182","authenticated-orcid":false,"given":"Bhausaheb","family":"Bagal","sequence":"additional","affiliation":[{"name":"11Department of Medicine, Tata Memorial Centre, Mumbai, India"},{"name":"12Department of Medicine, Homi Bhabha National Institute, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur S.","family":"Raje","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"issue":"6","key":"2025092310321050100_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2025092310321050100_bib2","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"24","key":"2025092310321050100_bib3","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"2025092310321050100_bib4","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025092310321050100_bib5","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood-2023-182388","article-title":"Updated safety and efficacy results of Abbv-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed\/refractory multiple myeloma [abstract]","volume":"142","author":"Vij","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2025092310321050100_bib6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025092310321050100_bib7","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2023-187706","article-title":"Talquetamab + pomalidomide in patients with relapsed\/refractory multiple myeloma: safety and preliminary efficacy results from the phase 1b monumenTAL-2 study [abstract]","volume":"142","author":"Matous","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025092310321050100_bib8","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood-2024-210520","article-title":"Efficacy of elranatamab (ELRA) in combination with carfilzomib (CFZ) and dexamethasone (DEX) in the phase 1b MagnetisMM-20 trial in relapsed or refractory multiple myeloma (RRMM) [abstract]","volume":"144","author":"Tomasson","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025092310321050100_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41408-024-01129-0","article-title":"Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel","volume":"14","author":"Banerjee","year":"2024","journal-title":"Blood Cancer J"},{"issue":"27","key":"2025092310321050100_bib10","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future","volume":"41","author":"Holstein","year":"2023","journal-title":"J Clin Oncol"},{"issue":"18","key":"2025092310321050100_bib11","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/bloodadvances.2024013461","article-title":"Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma","volume":"8","author":"Ludwig","year":"2024","journal-title":"Blood Adv"},{"issue":"13","key":"2025092310321050100_bib12","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"issue":"19","key":"2025092310321050100_bib13","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2025092310321050100_bib14","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1016\/j.ymthe.2025.03.048","article-title":"Non-relapse mortality with bispecific antibodies: a systematic review and meta-analysis in lymphoma and multiple myeloma","volume":"33","author":"Tix","year":"2025","journal-title":"Mol Ther"},{"issue":"25","key":"2025092310321050100_bib15","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJM196712212772503","article-title":"Role of gamma globulin for immunoprophylaxis in multiple myeloma","volume":"277","author":"Salmon","year":"1967","journal-title":"N Engl J Med"},{"issue":"8905","key":"2025092310321050100_bib16","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet"},{"key":"2025092310321050100_bib17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clim.2017.11.014","article-title":"Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial","volume":"191","author":"Vacca","year":"2018","journal-title":"Clin Immunol"},{"issue":"7","key":"2025092310321050100_bib18","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/bloodadvances.2023011231","article-title":"Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy","volume":"8","author":"McQuilten","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"2025092310321050100_bib19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM199107113250202","article-title":"Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia","volume":"325","author":"Weeks","year":"1991","journal-title":"N Engl J Med"},{"issue":"5","key":"2025092310321050100_bib20","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/10428190902856824","article-title":"Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis","volume":"50","author":"Raanani","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2025092310321050100_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41408-024-01107-6","article-title":"IgG replacement in multiple myeloma","volume":"14","author":"Wonnaparhown","year":"2024","journal-title":"Blood Cancer J"},{"issue":"9","key":"2025092310321050100_bib22","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1182\/bloodadvances.2023012047","article-title":"Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies","volume":"8","author":"Carrillo de Albornoz","year":"2024","journal-title":"Blood Adv"},{"issue":"10","key":"2025092310321050100_bib23","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.clml.2023.05.008","article-title":"Recommendations for management of secondary antibody deficiency in multiple myeloma","volume":"23","author":"Giralt","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2025092310321050100_bib24","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5","key":"2025092310321050100_bib25","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"issue":"1","key":"2025092310321050100_bib26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"5","key":"2025092310321050100_bib27","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"2025092310321050100_bib28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2025092310321050100_bib29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J"},{"issue":"3","key":"2025092310321050100_bib30","doi-asserted-by":"crossref","first-page":"308.e1","DOI":"10.1016\/j.jtct.2023.12.016","article-title":"Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"20","key":"2025092310321050100_bib31","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.3346\/jkms.2025.40.e86","article-title":"Incidence and characteristics of infectious complications in multiple myeloma patients treated with bispecific antibodies","volume":"40","author":"Park","year":"2025","journal-title":"J Korean Med Sci"},{"issue":"1","key":"2025092310321050100_bib32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","article-title":"Comparison of infectious complications with BCMA-directed therapies in multiple myeloma","volume":"14","author":"Nath","year":"2024","journal-title":"Blood Cancer J"},{"issue":"5","key":"2025092310321050100_bib33","doi-asserted-by":"crossref","first-page":"e14123","DOI":"10.1111\/tid.14123","article-title":"Characteristics and outcome of infectious complications after autologous hematopoietic cell transplantation in multiple myeloma patients","volume":"25","author":"Jandial","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"2025092310321050100_bib34","doi-asserted-by":"crossref","first-page":"e2400033","DOI":"10.1200\/GO.24.00033","article-title":"Factors associated with survival among patients with multiple myeloma in Northeastern Tanzania","volume":"10","author":"Raza","year":"2024","journal-title":"JCO Glob Oncol"},{"issue":"11","key":"2025092310321050100_bib35","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.3324\/haematol.2023.283003","article-title":"Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen","volume":"108","author":"Palmen","year":"2023","journal-title":"Haematologica"},{"issue":"7","key":"2025092310321050100_bib36","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/14796694.2025.2461430","article-title":"Patient preferences for triple-class-exposed relapsed or refractory multiple myeloma treatment: a discrete-choice study","volume":"21","author":"Ailawadhi","year":"2025","journal-title":"Future Oncol"},{"issue":"suppl 1","key":"2025092310321050100_bib37","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood-2024-199374","article-title":"Effects of intravenous immunoglobulin supplementation (IVIG) on infections in recipients of teclistamab therapy for multiple myeloma (MM): a multi-institutional study [abstract]","volume":"144","author":"Cheruvalath","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025092310321050100_bib38","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"2025092310321050100_bib39","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"issue":"11","key":"2025092310321050100_bib40","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/infdis\/jiu334","article-title":"Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses","volume":"210","author":"Jegaskanda","year":"2014","journal-title":"J Infect Dis"},{"issue":"7","key":"2025092310321050100_bib41","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/cid\/ciad368","article-title":"Commercial immunoglobulin products contain neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 spike protein","volume":"77","author":"Upasani","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2025092310321050100_bib42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.anai.2024.09.001","article-title":"Outcomes of intravenous immunoglobulin treatment of immunocompromised patients with viral respiratory infections","volume":"134","author":"Moughames","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"2025092310321050100_bib43","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1200\/OP.20.00312","article-title":"Changes in intravenous immunoglobulin usage for hypogammaglobulinemia after implementation of a stewardship program","volume":"17","author":"Derman","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"6","key":"2025092310321050100_bib44","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"issue":"suppl 16","key":"2025092310321050100_bib45","doi-asserted-by":"crossref","first-page":"7530","DOI":"10.1200\/JCO.2025.43.16_suppl.7530","article-title":"Assessment of normal plasma cell biomarkers after arlocabtagene autoleucel (arlo-cel) treatment in patients with \u22653L relapsed refractory multiple myeloma (MM) [abstract]","volume":"43","author":"Jordahl","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025092310321050100_bib46","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1182\/blood-2023-190749","article-title":"Flat dose intravenous immunoglobulin primary infection prophylaxis in multiple myeloma patients on bispecific antibody therapy: vanderbilt experience [abstract]","volume":"142","author":"Marneni","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2025092310321050100_bib47","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3324\/haematol.2023.283590","article-title":"The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma","volume":"109","author":"Hammons","year":"2024","journal-title":"Haematologica"},{"issue":"6","key":"2025092310321050100_bib48","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"suppl 1","key":"2025092310321050100_bib49","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1182\/blood-2024-205481","article-title":"Depletion of mature B cells and of normal plasma cells (PC) behind the higher incidence of infections after anti-BCMA vs anti-GPRC5D bispecific antibodies (bsAb) in relapsed refractory multiple myeloma (RRMM) [abstract]","volume":"144","author":"Jelinek","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025092310321050100_bib50","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood-2024-200181","article-title":"Teclistamab, daratumumab, and pomalidomide in patients with relapsed\/refractory multiple myeloma: results from the Majestec-2 cohort a and Trimm-2 studies [abstract]","volume":"144","author":"D'Souza","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2025092310321050100_bib51","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41375-025-02610-w","article-title":"Time for a paradigm shift in immunotherapy-based BCMA\/CD3 bispecific drug development in multiple myeloma","volume":"39","author":"Leleu","year":"2025","journal-title":"Leukemia"},{"issue":"1","key":"2025092310321050100_bib52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-025-01254-4","article-title":"Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients","volume":"15","author":"Chunara","year":"2025","journal-title":"Blood Cancer J"},{"issue":"6","key":"2025092310321050100_bib53","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/ajco.13515","article-title":"Longitudinal study of intravenous versus subcutaneous immunoglobulin replacement therapy in hematological malignancy","volume":"17","author":"Windegger","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"issue":"7","key":"2025092310321050100_bib54","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.clml.2024.02.013","article-title":"Financial toxicity, time toxicity, and quality of life in multiple myeloma","volume":"24","author":"Banerjee","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"2025092310321050100_bib55","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.3390\/cancers16183190","article-title":"Immunoglobulin replacement therapy: insights into multiple myeloma management","volume":"16","author":"Saltarella","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2025092310321050100_bib56","doi-asserted-by":"crossref","first-page":"108419","DOI":"10.1016\/j.clim.2020.108419","article-title":"Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): a retrospective multicenter study","volume":"215","author":"Legendre","year":"2020","journal-title":"Clin Immunol"},{"issue":"7","key":"2025092310321050100_bib57","doi-asserted-by":"crossref","first-page":"A432","DOI":"10.1016\/j.jval.2016.09.498","article-title":"Cost minimization analysis for the treatment of primary immunodeficiency disease (Pidd) in the Mexican Social Security Institute in 2016","volume":"19","author":"Maciel","year":"2016","journal-title":"Value in Health"},{"issue":"6","key":"2025092310321050100_bib58","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/jca.21646","article-title":"Cost-minimization analysis in the Indian subcontinent for treating Guillain Barre syndrome patients with therapeutic plasma exchange as compared to intravenous immunoglobulin","volume":"33","author":"Maheshwari","year":"2018","journal-title":"J Clin Apher"},{"issue":"8","key":"2025092310321050100_bib59","doi-asserted-by":"crossref","first-page":"e022862","DOI":"10.1136\/bmjopen-2018-022862","article-title":"Small volume plasma exchange for Guillain-Barr\u00e9 syndrome in resource-limited settings: a phase II safety and feasibility study","volume":"8","author":"Islam","year":"2018","journal-title":"BMJ Open"},{"issue":"5","key":"2025092310321050100_bib60","doi-asserted-by":"crossref","first-page":"e458","DOI":"10.1200\/JOP.18.00563","article-title":"National Comprehensive Cancer Network infusion efficiency workgroup study: optimizing patient flow in infusion centers","volume":"15","author":"Sugalski","year":"2019","journal-title":"J Oncol Pract"},{"issue":"4","key":"2025092310321050100_bib61","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10198-021-01278-0","article-title":"The cost of chemotherapy administration: a systematic review and meta-analysis","volume":"22","author":"Sohi","year":"2021","journal-title":"Eur J Health Econ"},{"issue":"11","key":"2025092310321050100_bib62","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/vox.13725","article-title":"Navigating the Asia-Pacific region plasma therapies landscape: insights from the 2023 Asia-Pacific Plasma Leaders' Network meetings","volume":"119","author":"Bhatnagar","year":"2024","journal-title":"Vox Sang"},{"issue":"suppl 16","key":"2025092310321050100_bib63","doi-asserted-by":"crossref","first-page":"e19004","DOI":"10.1200\/JCO.2024.42.16_suppl.e19004","article-title":"Flat dose intravenous immunoglobulin (IVIG) for primary infection prophylaxis after CAR-T for B-cell non-Hodgkin lymphoma (B-NHL)","volume":"42","author":"Lessans","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025092310321050100_bib64","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1017\/S026646232400028X","article-title":"A systematic review of the cost and cost-effectiveness of immunoglobulin treatment in patients with hematological malignancies","volume":"40","author":"Carrillo de Albornoz","year":"2024","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"2025092310321050100_bib65","doi-asserted-by":"crossref","first-page":"94","DOI":"10.14196\/mjiri.31.94","article-title":"Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies","volume":"31","author":"Shabaninejad","year":"2017","journal-title":"Med J Islam Repub Iran"},{"issue":"suppl 1","key":"2025092310321050100_bib66","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2249.2009.04027.x","article-title":"Subcutaneous immunoglobulin: opportunities and outlook","volume":"158","author":"Misbah","year":"2009","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2025092310321050100_bib67","doi-asserted-by":"crossref","first-page":"102715","DOI":"10.1016\/j.transci.2019.102715","article-title":"Plasma fractionation in countries with limited infrastructure and low-\/medium income: how to move forward?","volume":"59","author":"Burnouf","year":"2020","journal-title":"Transfus Apher Sci"},{"issue":"5","key":"2025092310321050100_bib68","doi-asserted-by":"crossref","first-page":"103987","DOI":"10.1016\/j.transci.2024.103987","article-title":"Towards personalized and rational use of immunoglobulins amid expanding indications and shortages","volume":"63","author":"Goubran","year":"2024","journal-title":"Transfus Apher Sci"},{"issue":"9","key":"2025092310321050100_bib69","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/vox.13698","article-title":"Generating pathways to domestically sourced plasma-derived medicinal products: report from a workshop by the International Plasma and Fractionation Association and the Working Party on Global Blood Safety of the International Society of Blood Transfusion","volume":"119","author":"Farrugia","year":"2024","journal-title":"Vox Sang"},{"issue":"2","key":"2025092310321050100_bib70","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/vox.13516","article-title":"Stepwise options for preparing therapeutic plasma proteins from domestic plasma in low- and middle-income countries","volume":"119","author":"Burnouf","year":"2024","journal-title":"Vox Sang"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/18\/4720\/2412583\/blooda_adv-2025-016490-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/18\/4720\/2412583\/blooda_adv-2025-016490-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:36:04Z","timestamp":1758638164000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/18\/4720\/546292\/Immunoglobulin-prophylaxis-should-be-initiated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":70,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,9,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016490","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,23]]},"published":{"date-parts":[[2025,9,16]]}}}